ACUTE TOXICITY STUDIES OF A NEW HBV IMMUNOTHERAPEUTIC AGENT MBRI-98304 IN RATS AND BEAGLE DOGS

  • Huang, Zai-Zhi (College of Veterinary Medicine, Chungbuk National University) ;
  • Jung, Eun-Yong (College of Veterinary Medicine, Chungbuk National University) ;
  • Zhang, Hu-Song (College of Veterinary Medicine, Chungbuk National University) ;
  • Kim, Dae-Joong (College of Veterinary Medicine, Chungbuk National University) ;
  • Nam, Sang-Yoon (College of Veterinary Medicine, Chungbuk National University) ;
  • Kang, Jong-Koo (College of Veterinary Medicine, Chungbuk National University)
  • Published : 2001.10.01

Abstract

The acute toxicity study of MBRI-98304, a new Hepatitis B virus (HBV) immunotherapeutic agent, was performed in Sprague-Dawley rats (7 weeks old) and Beagle dogs (4 months old). MBRI-98304 was injected intramuscularly at a single dosage of 0, 20, 100, 500, 2, 500, and 12, 500 $\mu\textrm{g}$/kg in rats and 0, 200, 1, 000, and 5, 000 $\mu\textrm{g}$/kg in Beagle dogs for 2 weeks daily. There were no deaths or clinical signs.(omitted)

Keywords